Solara Active Pharma Sciences Ltd
NSE:SOLARA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Solara Active Pharma Sciences Ltd
NSE:SOLARA
|
25.6B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Solara Active Pharma Sciences Ltd
Glance View
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Solara Active Pharma Sciences Ltd is 0.5%, which is above its 3-year median of -16%.
Over the last 3 years, Solara Active Pharma Sciences Ltd’s Net Margin has increased from -14.6% to 0.5%. During this period, it reached a low of -44% on Mar 31, 2024 and a high of 2% on Jun 30, 2025.
